vs
Pacira BioSciences, Inc.（PCRX）与Resolute Holdings Management, Inc.（RHLD）财务数据对比。点击上方公司名可切换其他公司
Pacira BioSciences, Inc.的季度营收约是Resolute Holdings Management, Inc.的1.7倍（$196.9M vs $117.7M），Resolute Holdings Management, Inc.自由现金流更多（$189.2M vs $43.5M）
Pacira BioSciences是一家专科制药企业，专注于非阿片类疼痛管理药物的研发与商业化，核心产品线面向术后镇痛场景，服务以美国为主的医院、门诊手术中心等医疗服务机构，同时推进部分国际市场的拓展工作。
Resolute Holdings Management, Inc.是一家澳大利亚矿业企业，核心业务布局于非洲地区，目前运营两座金矿，分别为位于马里的 Syama 金矿和塞内加尔的 Mako 金矿，专注于黄金资源的勘探、开采及相关运营管理工作。
PCRX vs RHLD — 直观对比
营收规模更大
PCRX
是对方的1.7倍
$117.7M
自由现金流更多
RHLD
多$145.8M
$43.5M
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $196.9M | $117.7M |
| 净利润 | — | $-1.7M |
| 毛利率 | 79.5% | 55.7% |
| 营业利润率 | 1.2% | 30.2% |
| 净利率 | — | -1.5% |
| 营收同比 | 5.1% | — |
| 净利润同比 | — | — |
| 每股收益（稀释后） | $0.05 | $-0.20 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PCRXRHLD
| Q4 25 | $196.9M | $117.7M | ||
| Q3 25 | $179.5M | $120.9M | ||
| Q2 25 | $181.1M | $119.6M | ||
| Q1 25 | $168.9M | $103.9M | ||
| Q4 24 | $187.3M | — | ||
| Q3 24 | $168.6M | — | ||
| Q2 24 | $178.0M | — | ||
| Q1 24 | $167.1M | — |
净利润PCRXRHLD
| Q4 25 | — | $-1.7M | ||
| Q3 25 | $5.4M | $-231.0K | ||
| Q2 25 | $-4.8M | $-611.0K | ||
| Q1 25 | $4.8M | $-3.4M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-143.5M | — | ||
| Q2 24 | $18.9M | — | ||
| Q1 24 | $9.0M | — |
毛利率PCRXRHLD
| Q4 25 | 79.5% | 55.7% | ||
| Q3 25 | 80.9% | 59.0% | ||
| Q2 25 | 77.4% | 57.5% | ||
| Q1 25 | 79.7% | 52.5% | ||
| Q4 24 | 78.7% | — | ||
| Q3 24 | 76.9% | — | ||
| Q2 24 | 75.1% | — | ||
| Q1 24 | 71.6% | — |
营业利润率PCRXRHLD
| Q4 25 | 1.2% | 30.2% | ||
| Q3 25 | 3.5% | 34.3% | ||
| Q2 25 | 4.7% | 34.0% | ||
| Q1 25 | 1.2% | 24.7% | ||
| Q4 24 | 13.2% | — | ||
| Q3 24 | -82.8% | — | ||
| Q2 24 | 15.9% | — | ||
| Q1 24 | 7.9% | — |
净利率PCRXRHLD
| Q4 25 | — | -1.5% | ||
| Q3 25 | 3.0% | -0.2% | ||
| Q2 25 | -2.7% | -0.5% | ||
| Q1 25 | 2.8% | -3.2% | ||
| Q4 24 | — | — | ||
| Q3 24 | -85.1% | — | ||
| Q2 24 | 10.6% | — | ||
| Q1 24 | 5.4% | — |
每股收益（稀释后）PCRXRHLD
| Q4 25 | $0.05 | $-0.20 | ||
| Q3 25 | $0.12 | $-0.03 | ||
| Q2 25 | $-0.11 | $-0.07 | ||
| Q1 25 | $0.10 | $-0.39 | ||
| Q4 24 | $0.38 | — | ||
| Q3 24 | $-3.11 | — | ||
| Q2 24 | $0.39 | — | ||
| Q1 24 | $0.19 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $238.4M | $205.5M |
| 总债务越低越好 | $372.2M | $169.8M |
| 股东权益账面价值 | $693.1M | $6.5M |
| 总资产 | $1.3B | $333.4M |
| 负债/权益比越低杠杆越低 | 0.54× | 26.03× |
8季度趋势，按日历期对齐
现金及短期投资PCRXRHLD
| Q4 25 | $238.4M | $205.5M | ||
| Q3 25 | $246.3M | $148.0M | ||
| Q2 25 | $445.9M | $99.9M | ||
| Q1 25 | $493.6M | $71.0M | ||
| Q4 24 | $484.6M | — | ||
| Q3 24 | $453.8M | — | ||
| Q2 24 | $404.2M | — | ||
| Q1 24 | $325.9M | — |
总债务PCRXRHLD
| Q4 25 | $372.2M | $169.8M | ||
| Q3 25 | $376.7M | $173.4M | ||
| Q2 25 | $580.5M | $177.1M | ||
| Q1 25 | $583.4M | $180.7M | ||
| Q4 24 | $585.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益PCRXRHLD
| Q4 25 | $693.1M | $6.5M | ||
| Q3 25 | $727.2M | $10.8M | ||
| Q2 25 | $757.8M | $9.6M | ||
| Q1 25 | $798.5M | $8.9M | ||
| Q4 24 | $778.3M | — | ||
| Q3 24 | $749.6M | — | ||
| Q2 24 | $879.3M | — | ||
| Q1 24 | $892.2M | — |
总资产PCRXRHLD
| Q4 25 | $1.3B | $333.4M | ||
| Q3 25 | $1.3B | $293.2M | ||
| Q2 25 | $1.5B | $253.3M | ||
| Q1 25 | $1.6B | $214.3M | ||
| Q4 24 | $1.6B | — | ||
| Q3 24 | $1.5B | — | ||
| Q2 24 | $1.6B | — | ||
| Q1 24 | $1.6B | — |
负债/权益比PCRXRHLD
| Q4 25 | 0.54× | 26.03× | ||
| Q3 25 | 0.52× | 16.01× | ||
| Q2 25 | 0.77× | 18.42× | ||
| Q1 25 | 0.73× | 20.38× | ||
| Q4 24 | 0.75× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $43.7M | $196.1M |
| 自由现金流经营现金流 - 资本支出 | $43.5M | $189.2M |
| 自由现金流率自由现金流/营收 | 22.1% | 160.8% |
| 资本支出强度资本支出/营收 | 0.1% | 5.8% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $136.7M | $313.2M |
8季度趋势，按日历期对齐
经营现金流PCRXRHLD
| Q4 25 | $43.7M | $196.1M | ||
| Q3 25 | $60.8M | $59.6M | ||
| Q2 25 | $12.0M | $48.9M | ||
| Q1 25 | $35.5M | $18.4M | ||
| Q4 24 | $33.1M | — | ||
| Q3 24 | $53.9M | — | ||
| Q2 24 | $53.2M | — | ||
| Q1 24 | $49.1M | — |
自由现金流PCRXRHLD
| Q4 25 | $43.5M | $189.2M | ||
| Q3 25 | $57.0M | $58.6M | ||
| Q2 25 | $9.3M | $47.5M | ||
| Q1 25 | $26.9M | $17.8M | ||
| Q4 24 | $31.0M | — | ||
| Q3 24 | $49.8M | — | ||
| Q2 24 | $51.6M | — | ||
| Q1 24 | $46.3M | — |
自由现金流率PCRXRHLD
| Q4 25 | 22.1% | 160.8% | ||
| Q3 25 | 31.7% | 48.5% | ||
| Q2 25 | 5.1% | 39.7% | ||
| Q1 25 | 15.9% | 17.1% | ||
| Q4 24 | 16.6% | — | ||
| Q3 24 | 29.6% | — | ||
| Q2 24 | 29.0% | — | ||
| Q1 24 | 27.7% | — |
资本支出强度PCRXRHLD
| Q4 25 | 0.1% | 5.8% | ||
| Q3 25 | 2.2% | 0.8% | ||
| Q2 25 | 1.5% | 1.2% | ||
| Q1 25 | 5.1% | 0.6% | ||
| Q4 24 | 1.1% | — | ||
| Q3 24 | 2.4% | — | ||
| Q2 24 | 0.9% | — | ||
| Q1 24 | 1.7% | — |
现金转化率PCRXRHLD
| Q4 25 | — | — | ||
| Q3 25 | 11.20× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 7.37× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 2.82× | — | ||
| Q1 24 | 5.47× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PCRX
| EXPAREL | $155.8M | 79% |
| ZILRETTA | $33.0M | 17% |
| Iovera | $7.0M | 4% |
RHLD
暂无分部数据
